arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its ...
"At Zimbis, we're driven by the opportunity to make complex operations simpler for dental laboratories," said Louis Visser, President Zimbis. "By partnering with Argen, we're giving labs access to ...
Argen-X (ARGX) has delivered a 31.54% change over the past year, with a 52-week range between 456.60 and 810.00. What Is the Average Daily Trading Volume of Argen-X (ARGX)? The average daily trading ...
ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing stress ...
ROTTERDAM, The Netherlands, September 10 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) ...
The facility will operate under arGEN-X’ CSO Prof. Dr. Hans de Haard, and CDO Dr. Torsten Dreier, who have already attracted an experienced international core team of antibody discovery and ...
ARGX-110-based combination therapies have demonstrated potential in treatment-resistant cancers. arGEN-X, a clinical-stage biopharmaceutical company, and the Clinical Research Department of the ...
CYPRESS, Texas—Argen Polymer L.L.C., a specialist in materials development, consulting, testing and analysis, just announced three new advances for the company: • ISO accreditation in January 2017, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results